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Short Communication
Preferential delivery of liposome-incorporated porphyrins to
neoplastic cells in tumour-bearing rats.
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Considerable interest has been aroused in recent
years by the possibility of inducing the regression of
different kinds of tumours in experimental animals
(Granelli et al., 1975; Dougherty et al., 1975) and
humans (Dougherty et al., 1979; Forbes et al., 1980;
Hayata et al., 1982) by irradiation with red light
(-.630nm) in the presence of hematoporphyrin
(Hp) and its derivative (HpD). HpD and Hp are
powerful cell-photosensitizing agents (Moan et al.,
1978; Kessel, 1977) and exhibit a preferential affinity
for neoplastic tissues (Figge et al., 1948; Gomer &
Dougherty, 1979; Jori et al., 1979). At present, the
phototherapeutic treatment utilizes relatively water-
soluble porphyrins which are injected into the
blood stream and carried to the various tissues as a
complex with serum proteins. There is also
considerable controversy regarding the purity of Hp
and HpD and the actual therapeutically-active
components of these drugs (Berenbaum et al., 1982).
In this communication we discuss the feasibility of
obtaining a highly preferential localization of the
porphyrins Hp and its dimethylester (HpdiMe) in
neoplastic cells when the porphyrin is incorporated
into dipalmitoyl-diphosphatidyl-choline (DPPC)
liposomes prior to administration. In previous
papers (Tomio et al., 1980, 1982a), the distribution
of Hp in normal and tumour-bearing rats after i.p.
or i.v. administration of the porphyrin free in
aqueous solution was studied. Hp and HpdiMe
were supplied by Porphyrin Products (Logan,
Utah). L-ae-DPPC was the 99% pure synthetic
crystalline derivative (Sigma). Liposomes,
containing -2ml% Hp or HpdiMe, were prepared
by dissolving 51.4mg of DPPC in lOml of mM
porphyrin solution in chloroform-methanol (9: 1,
v/v).
After thorough mixing for -30min the solvent
was removed by vacuum rotary evaporation at
30°C. The solid was resuspended in 1Oml 0.01 M
Universita' di Padova and 2Divisione di Radioterapia,
phospate buffer at pH 7.4 containing 150mMNaCl
and the cloudy solution then sonicated for 30min at
50°C. In this way, the final solution should contain
unilamellar liposomes, which remain stable for
about 48h if kept in the refrigerator under nitrogen.
Under these conditions both Hp and HpdiMe are
completely incorporated in a monomeric form into
the liposomal structure as indicated by the red-shift
of the Soret absorption maximum (maxm=405nm)
and of the fluorescence emission spectrum (Amax
=624nm). Incubation of liposomes in the buffer
medium for up to 5 days showed that HpdiMe
remains associated with the phospholipid, whereas
there was an almost 25% loss of Hp. Aliquots of the
final solution corresponding to 10mg porphyrin
Kg-1 rat body weight were injected i.p. to Wistar
albino rats, 20+1 days old, either normal or
bearing an s.c. solid Yoshida hepatoma AH-130
(Yoshida, 1949; Sato, 1955). The management of
tumours and rats has been described previously
(Tomio et al., 1982a). At fixed times, rats were
sacrificed, tumours and selected tissues (liver,
kidneys and skin) removed and the porphyrin
content determined by spectrophotofluorimetric
analysis (Jori et al., 1979) after extraction of the
porphyrins from the tissues with 2% sodium
dodecyl sulphate (SDS). Control studies showed
that both Hp and HpdiMe readily partition into
SDS micelles.
The recoveries of Hp and HpdiMe at various
times between 1 h and 72h after porphyrin
administration are shown in Tables I and II,
respectively. As regards Hp, the results obtained
with normal rats resemble those found after i.p. or
i.v. injection of Hp in homogeneous solution, since
maximal accumulation is observed in liver at 1 h
(Tomio et al., 1980). The presence of the tumour
reduced the amount of Hp migrating to the liver.
However, in both cases, an appreciable fraction of
Hp appeared to be eliminated via the kidneys.
Neoplastic tissues again accumulated a remarkably
larger amount of Hp, the cellular concentration of
which was still increasing at 72h after
The Macmillan Press Ltd., 1983
Correspondence: G. Jon
Received 10 February 1983; accepted 16 May 1983.308 G. JORI et al.
Table I Recovery of liposomal hematoporphyrin (ngg-1
tissue) from selected tissues of normal and tumour-bearing
rats.
lime after Normal rats Tumour-bearing rats
administration
(h) Liver Kidney Liver Kidney Tmour
1 34.0 12.4 9.5 11.4 27.9
6 9.6 7.5 3.6 10.3 45.9
24 4.2 6.3 2.0 8.7 55.8
72 2.0 2.3 2.3 2.4 79.1
Table II Recovery of liposomal hematoporphyrin
dimethylester (ngg-1 of tissue) from selected tissues of
normal and tumour-bearing rats.
7ime after Normal rats Dmour-bearing rats
administration
(h) Liver Kidney Liver Kidney Tumour
1 18.6 21.5 15.3 10.8
6 25.6 29.4 25.3 9.1 17.2
24 32.5 34.0 21.1 6.0 20.5
72 3.8 10.1 3.3 1.7 25.0
administration, whereas normally clearance of the
Hp from tumour cells begins at 24h after
administration (Tomio et al., 1980, 1982b). Thus, a
tumour:liver ratio of Hp concentration as high as
34 was reached at 72h compared with a 4 5 ratio
typical of the same rats, after normal Hp
administration. Liposome-bound HpdiMe migrated
to the various tissues at a slower rate than Hp
although its clearance was also much slower.
However, in this case also, the porphyrin was
essentially completely eliminated from normal
tissues at 72h after administration, so that a
tumour :liver ratio of -8 was reached. In any case,
the presence of the tumour appeared to reduce
mainly the amount of HpdiMe migrating to the
kidneys.
The tumour:liver ratios of porphyrin
concentration found in the present investigation are
higher than those reported by other authors
(Gomer & Dougherty, 1979; Moan et al., 1982).
This discrepancy may be due to differences in
tumour types. However, preliminary experiments on
Hp distribution in mice bearing the MBL-2
lymphoma suggest that Hp has a greater affinity
towards this tumour type also: e.g., tumour:liver
ratios of Hp concentration as high as 5.94 and 6.59
are found at 24h and, 72h respectively after i.p.
administration of 2.5mgkg-' Hp to lymphoma-
bearing mice. It is worth emphasizing that analysis
of Hp from Porphyrin Products by HPLC indicates
that this porphyrin sample contains a significant
percentage of the tumour-localizing component
which is also present in HpD (Dougherty, T.J.,
personal comunication). Hp and HpdiMe also
accumulate in the skin, although no regular time-
dependence is observed. In particular, porphyrin
recoveries ranging between 10-40ngg-1 are
obtained from the skin of both normal and tumour-
bearing rats at relatively short times (1-6h) after
injection. At time intervals longer than 24h the
amounts of residual porphyrin in the skin decrease
below lOngg-'. This fact should reduce the
probability of important side effects due to the
onsetofskinphotosensitivity, which has actuallybeen
exhibited by patients subjected to phototherapy
(Dougherty, 1978). However, this point deserves
further investigation, since skin damage may limit
the light doses that can be administered.
The different behaviour of liposomal Hp, as
compared with Hp in homogeneous solution,
probably implies a different mechanism of
interaction with subcellular receptors and/or serum
proteins. Thus, the significant amount of liposomal
Hp which is recovered from the kidneys of both
normal and tumour-bearing rats suggests that an
important fraction of liposome-bound Hp is not
complexed with serum albumin. It is conceivable
that the gradual accumulation of Hp by tumour
cells up to 72h after administration of the
porphyrin reflects a slow release of circulating Hp
from the liposomes to the cell receptors. This
hypothesis is supported by the experiments with
liposomal HpdiMe. The latter porphyrin is
endowed with a greater lipid-solubility than Hp,
hence a consistently larger amount of porphyrin
remains in the circulation and is found in the
kidneys. Moreover, its accumulation by tumour
cells occurs at a slower rate.
The detailed processes controlling the preferential
uptake of porphyrins by tumour cells are still
partially unknown. We are presently pursuing our
studies with free and liposome-bound porphyrins to
elucidate the detailed mechanism of their
interactions with subcellular structures.
In any case, the prolonged retention of elevated
amounts of liposomal Hp and HpdiMe opens the
possibility of improving the efficacy of phototherapy
whilst minimizing the onset of undesired side effects.
Actually, preliminary experiments performed in our
laboratory indicate a rapid regression of the above
tumour if the rats are exposed to red light at
approximately 72h after i.p. injection of liposomal
Hp or HpdiMe.
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